Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2023-06-01 Sale |
2023-06-02 7:48 pm |
ARS Pharmaceuticals Inc. | SPRY | Shawver Laura Director |
100,000 | $6.8404 | $684,041 | 643,281 (Direct) |
View |
| 2022-11-09 Sale |
2023-05-10 4:53 pm |
ARS Pharmaceuticals Inc. | SPRY | Shawver Laura Director |
143,896 | $5.4246 | $780,579 | 859,240 (Direct) |
View |
| 2022-11-29 Purchase |
2022-12-01 4:31 pm |
ARS Pharmaceuticals Inc. | SPRY | Scott Kathleen D. Chief Financial Officer |
8,250 | $6.2432 | $51,506 | 8,250 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2023-06-27 Option Award |
2023-06-28 9:00 pm |
N/A 2033-06-26 |
ARS Pharmaceuticals Inc. | SPRY | Islam Saqib Director |
40,000 | $0 | 40,000 (Direct) |
View |
| 2023-06-01 Exercise |
2023-06-02 7:48 pm |
N/A N/A |
ARS Pharmaceuticals Inc. | SPRY | Shawver Laura Director |
100,000 | $1.27 | 643,281 (Direct) |
View |
| 2023-06-01 Exercise |
2023-06-02 7:48 pm |
N/A 2030-04-28 |
ARS Pharmaceuticals Inc. | SPRY | Shawver Laura Director |
100,000 | $0 | 643,281 (Direct) |
View |
| 2023-05-08 Exercise |
2023-05-10 4:53 pm |
N/A N/A |
ARS Pharmaceuticals Inc. | SPRY | Shawver Laura Director |
100,000 | $1.27 | 859,240 (Direct) |
View |
| 2023-05-08 Exercise |
2023-05-10 4:53 pm |
N/A 2030-04-28 |
ARS Pharmaceuticals Inc. | SPRY | Shawver Laura Director |
100,000 | $0 | 859,240 (Direct) |
View |
| 2023-01-03 Option Award |
2023-01-05 5:00 pm |
N/A 2033-01-02 |
ARS Pharmaceuticals Inc. | SPRY | Scott Kathleen D. Chief Financial Officer |
50,000 | $0 | 50,000 (Direct) |
View |
| 2023-01-03 Option Award |
2023-01-05 5:00 pm |
N/A 2033-01-02 |
ARS Pharmaceuticals Inc. | SPRY | Fitzpatrick Alexander A Chief Legal Officer |
700,000 | $0 | 700,000 (Direct) |
View |
| 2023-01-03 Option Award |
2023-01-05 5:00 pm |
N/A 2033-01-02 |
ARS Pharmaceuticals Inc. | SPRY | Chakma Justin Chief Business Officer |
165,000 | $0 | 165,000 (Direct) |
View |
| 2023-01-03 Option Award |
2023-01-05 5:00 pm |
N/A 2033-01-02 |
ARS Pharmaceuticals Inc. | SPRY | Dorsey Brian Chief Operating Officer |
145,000 | $0 | 145,000 (Direct) |
View |
| 2023-01-03 Option Award |
2023-01-05 5:00 pm |
N/A 2033-01-02 |
ARS Pharmaceuticals Inc. | SPRY | Karas Eric Chief Commercial Officer |
50,000 | $0 | 50,000 (Direct) |
View |
| 2023-01-03 Option Award |
2023-01-05 5:00 pm |
N/A 2033-01-02 |
ARS Pharmaceuticals Inc. | SPRY | Tanimoto Sarina Chief Medical Officer 10% Owner |
1,450,000 | $0 | 1,450,000 (Direct) |
View |
| 2023-01-03 Option Award |
2023-01-05 5:00 pm |
N/A 2033-01-02 |
ARS Pharmaceuticals Inc. | SPRY | Lowenthal Richard E President and CEO 10% Owner |
1,450,000 | $0 | 1,450,000 (Direct) |
View |
Ownership |
2022-12-09 5:06 pm |
2018-11-29 2028-11-28 |
ARS Pharmaceuticals Inc. | SPRY | Dorsey Brian Chief Operating Officer |
0 | $0 | 603,359 (Direct) |
View |
Ownership |
2022-11-10 7:48 pm |
N/A N/A |
ARS Pharmaceuticals Inc. | SPRY | Flynn James E Deerfield Mgmt III L.P. DEERFIELD MANAGEMENT COMPANY L.P. (SERIES C) Deerfield Private Design Fund III L.P. Deerfield Mgmt IV L.P. Deerfield Private Design Fund IV L.P. Director by deputization Director 10% Owner |
0 | $0 | 11,077,928 (Indirect) |
View |
| 2022-11-08 Option Award |
2022-11-10 6:00 pm |
N/A 2029-07-05 |
ARS Pharmaceuticals Inc. | SPRY | Chakma Justin Chief Business Officer |
603,753 | $0 | 840,133 (Direct) |
View |
| 2022-11-08 Option Award |
2022-11-10 6:00 pm |
N/A 2031-11-30 |
ARS Pharmaceuticals Inc. | SPRY | Shah Pratik Pratik Shah Living Trust dated June 15 2011 Director 10% Owner |
10,510,774 | $0 | 10,510,774 (Direct) |
View |
| 2022-11-08 Option Award |
2022-11-10 6:00 pm |
N/A 2032-05-24 |
ARS Pharmaceuticals Inc. | SPRY | Karas Eric Chief Commercial Officer |
614,588 | $0 | 614,588 (Direct) |
View |
| 2022-11-08 Option Award |
2022-11-10 6:00 pm |
N/A 2029-07-05 |
ARS Pharmaceuticals Inc. | SPRY | SCHNEIDER PHILLIP M Director |
230,470 | $0 | 230,470 (Direct) |
View |
| 2022-11-08 Option Award |
2022-11-10 6:00 pm |
N/A N/A |
ARS Pharmaceuticals Inc. | SPRY | RA CAPITAL MANAGEMENT L.P. RA Capital Healthcare Fund LP RA Capital Nexus Fund II L.P. Kolchinsky Peter Shah Rajeev M. Director |
3,009,678 | $0 | 902,904 (Indirect) |
View |
| 2022-11-08 Option Award |
2022-11-10 6:00 pm |
N/A 2029-12-16 |
ARS Pharmaceuticals Inc. | SPRY | Tanimoto Sarina Chief Medical Officer 10% Owner |
6,737,930 | $0 | 9,291,934 (Direct) |
View |
| 2022-11-08 Option Award |
2022-11-10 6:00 pm |
N/A 2029-12-16 |
ARS Pharmaceuticals Inc. | SPRY | Lowenthal Richard E President and CEO 10% Owner |
11,914,752 | $0 | 7,587,898 (Direct) |
View |
| 2022-11-08 Option Award |
2022-11-10 6:00 pm |
N/A 2031-06-15 |
ARS Pharmaceuticals Inc. | SPRY | SAUNDERS BRENT L Director |
744,597 | $0 | 744,597 (Direct) |
View |
| 2022-11-08 Option Award |
2022-11-10 6:00 pm |
N/A 2029-07-04 |
ARS Pharmaceuticals Inc. | SPRY | Kelly Michael Director |
271,837 | $0 | 271,837 (Direct) |
View |
| 2022-11-08 Option Award |
2022-11-10 6:00 pm |
N/A N/A |
ARS Pharmaceuticals Inc. | SPRY | Dadoo Rajeev Director |
3,009,677 | $0 | 3,009,677 (Indirect) |
View |
| 2022-11-08 Option Award |
2022-11-10 6:00 pm |
N/A 2032-03-01 |
ARS Pharmaceuticals Inc. | SPRY | Scott Kathleen D. Chief Financial Officer |
827,330 | $0 | 827,330 (Direct) |
View |
Ownership |
2022-09-08 5:04 pm |
N/A N/A |
Silverback Therapeutics Inc. | SBTX | Pepe Jeffrey C. Interim CEO and GC |
0 | $0 | 427,750 (Direct) |
View |
| 2022-08-05 Exercise |
2022-08-09 4:38 pm |
N/A N/A |
Silverback Therapeutics Inc. | SBTX | Shawver Laura Chief Executive Officer |
78,740 | $1.27 | 657,239 (Direct) |
View |
| 2022-08-05 Exercise |
2022-08-09 4:38 pm |
N/A 2030-04-28 |
Silverback Therapeutics Inc. | SBTX | Shawver Laura Chief Executive Officer |
78,740 | $0 | 657,239 (Direct) |
View |
| 2022-06-10 Option Award |
2022-06-13 7:52 pm |
N/A 2032-06-09 |
Silverback Therapeutics Inc. | SBTX | Thompson Peter A. Director 10% Owner |
18,000 | $0 | 18,000 (Direct) |
View |